Since it was first described by international health organizations in 2006, extensively drug-resistant tuberculosis has been documented in 49 countries. In addition, more than 80 countries are coping with multi-drug resistant tuberculosis. How are we addressing the rapid emergence of these significant threats to tuberculosis treatment and control programs across the world? In which countries are we seeing significant progress in treating both forms of tuberculosis? Dr. Sonya Shin, assistant professor of medicine at Harvard Medical School, contours lessons for the global struggle against TB from her work in South America and Asia with host Dr. Mark Nolan Hill.
Successful Treatment of MDR and XDR-TB
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Since it was first described by international health organizations in 2006, extensively drug-resistant tuberculosis has been documented in 49 countries. In addition, more than 80 countries are coping with multi-drug resistant tuberculosis. How are we addressing the rapid emergence of these significant threats to tuberculosis treatment and control programs across the world? In which countries are we seeing significant progress in treating both forms of tuberculosis? Dr. Sonya Shin, assistant professor of medicine at Harvard Medical School, contours lessons for the global struggle against TB from her work in South America and Asia with host Dr. Mark Nolan Hill.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
IgG4-RD Case Conversations: The Peculiarities of Kidney Involvement
IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference
Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D
HF Management for Patients with Comorbid Conditions
Level Up Your Skills: Tailoring Management of HF
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?